BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SenzaGen
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231112
DTEND;VALUE=DATE:20231116
DTSTAMP:20231109T141151Z
CREATED:20230824T070701Z
LAST-MODIFIED:20231109T141151Z
UID:30935-1699747200-1700092799@senzagen.com
SUMMARY:ACT 2023 Annual Meeting
DESCRIPTION:→ Booth #333\nSpotlight on difficult-to-test samples and in vitro quantitative potency assessment as an alternative to the Local Lymph Node Assay\nCome meet us at booth #333 and join our poster presentation to learn how the GARD assays are used to fill data gaps for skin sensitizing hazard and quantitative potency assessment\, providing a high performing and ethical alternative to animal testing. \n→ Joint poster with Takasago\nQuantitative potency assessment of skin sensitizers when developing novel fragrance ingredients\nPractical application of the GARDskin Dose-Response assay to derive a No Expected Sensitization Induction Level (NESIL) value for confirmatory human patch studies to determine safe use level for novel fragrance ingredients \n→ Hot topic\nIn vitro tests supporting Occupational Health\nOccupational allergic dermatitis and asthma are common workplace diseases. By using the in vitro GARD® assays to test for skin and respiratory sensitizers in combination\, it is possible to identify allergens in the work environment and take preventive action. \nCome by our booth to learn more! \n→ Discuss your toxicological risk assessment needs with us!\nMeet our in vitro experts\, Dr Andy Forreryd and Dr Tim Lindberg
URL:https://senzagen.com/event/act-2023-annual-meeting/
LOCATION:Orlando\, Florida\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/08/banner_ACT2023-scaled.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231116
DTEND;VALUE=DATE:20231118
DTSTAMP:20231108T143625Z
CREATED:20230824T072405Z
LAST-MODIFIED:20231108T143625Z
UID:30942-1700092800-1700265599@senzagen.com
SUMMARY:Annual Medical Device Biocompatibility Conference
DESCRIPTION:Presentation \n\nThe GARD®skin Medical Device assay for assessing the skin sensitizing potential of medical devices: A case study on the use of in vitro data in the biological evaluation for CE marking according to MDR\n\nKey Points \n\nA proof-of-concept study using the GARD®skin Medical Device assay to evaluate the skin sensitizing potential of medical device materials according to ISO 10993-10.\nA case study using in vitro data for the endpoints of cytotoxicity\, skin irritation and skin sensitization in the biological evaluation for CE-marking according to MDR to avoid animal testing while accelerating time to market.
URL:https://senzagen.com/event/annual-medical-device-biocompatibility-conference/
LOCATION:Berlin\, Germany
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/08/bicompatibility_berlin.jpg
END:VEVENT
END:VCALENDAR